Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease
NCT00018278Phase 4Completed
- Sponsor
- United States Department of Veterans Affairs
- Start
- Oct 1998
- Modality
- Reversible Covalent Inhibitors, Transdermal Patches, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4 trial of donepezil transdermal patch, rivastigmine and nicotine patch in Alzheimer's disease (AD) (3 arms), sponsored by United States Department of Veterans Affairs. Primary endpoint: Electrophysiological markers and predictors of cognitive and clinical treatment response. Started Oct 1998; status: completed.
02
Drugs
donepezil transdermal patchrivastigminenicotine patch
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00018278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00018278.